NZ782000B2 - Dosing of kras inhibitor for treatment of cancers - Google Patents

Dosing of kras inhibitor for treatment of cancers

Info

Publication number
NZ782000B2
NZ782000B2 NZ782000A NZ78200020A NZ782000B2 NZ 782000 B2 NZ782000 B2 NZ 782000B2 NZ 782000 A NZ782000 A NZ 782000A NZ 78200020 A NZ78200020 A NZ 78200020A NZ 782000 B2 NZ782000 B2 NZ 782000B2
Authority
NZ
New Zealand
Prior art keywords
cancer
antibody
medicament
chemotherapeutic
treatment
Prior art date
Application number
NZ782000A
Other versions
NZ782000A (en
Inventor
Victor J Cee
Haby Henary
James Russell Lipford
Original Assignee
Amgen Inc
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority claimed from PCT/US2020/032686 external-priority patent/WO2020232130A1/en
Publication of NZ782000A publication Critical patent/NZ782000A/en
Publication of NZ782000B2 publication Critical patent/NZ782000B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Provided herein are methods of administering a KRAS G12C inhibitor, namely AMG-510 as shown in the abstract drawing, to a cancer subject, using CA19-9 and CEA Biomarkers. Wherein the medicament comprises a total daily dosage of 960 mg.

Claims (24)

What is claimed:
1. Use of a compound having the following ure: , or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer in a subject in need thereof, wherein the treatment comprises administration of the compound to the t at a total daily amount of 960 mg.
2. The use of claim 1, wherein the cancer is non-small cell lung cancer, colorectal cancer, pancreatic cancer, appendix cancer, endometrial cancer, gastric cancer, small intestine cancer, nasal cavity cancer, bile duct , or skin cancer.
3. The use of claim 1 or claim 2, wherein the cancer is non-small cell lung cancer.
4. The use of any one of claims 1 to 3, wherein the cancer is locally advanced or metastatic non-small cell lung cancer.
5. The use of claim 1 or claim 2, wherein the cancer is ctal cancer.
6. The use of claim 1 or claim 2, n the cancer is pancreatic cancer.
7. The use of any one of claims 1 to 6, wherein the cancer is a KRAS G12C mutated cancer.
8. The use of any one of claims 1 to 7, wherein the subject, prior to start of treatment with the medicament, had undergone at least one other systemic cancer therapy.
9. The use of any one of claims 1 to 8, wherein the subject had undergone at least two other ic cancer therapies.
10. The use of any one of claims 1 to 9, wherein the medicament is to be stered orally.
11. The use of any one of claims 1 to 10, wherein the medicament is to be administered once daily.
12. The use of any one of claims 1 to 11, wherein the medicament is to be administered as a tablet.
13. The use of any one of claims 1 to 12, n the treatment further comprises administration of a chemotherapeutic.
14. The use of claim 13, n the chemotherapeutic comprises an anti-PD1 antibody.
15. The use of claim 14, wherein the anti-PD1 antibody is pembrolizumab, mab, or AMG 404.
16. The use of claim 14 or claim 15, wherein the D1 antibody is prembrolizumab.
17. The use of claim 14 or claim 15, wherein the anti-PD1 antibody is AMG 404.
18. The use of claim 13, wherein the chemotherapeutic comprises an anti-PDL1
19. The use of claim 18, wherein the anti-PDL1 antibody is atezolizumab, avelumab, or durvalumab.
20. The use of claim 19, wherein the anti-PDL1 antibody is atezolizumab.
21. The use of claim 13, wherein the chemotherapeutic comprises a MEK inhibitor.
22. The use of claim 21, wherein the MEK inhibitor is trametinib, pimasertib, PD- 325901, MEK162, TAK-733, GDC-0973, or AZD8330.
23. The use of claim 21 or claim 22, wherein the MEK inhibitor is trametinib.
24. The use of claim 13, wherein the chemotherapeutic comprises a CDK
NZ782000A 2020-05-13 Dosing of kras inhibitor for treatment of cancers NZ782000B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962847862P 2019-05-14 2019-05-14
US201962867747P 2019-06-27 2019-06-27
PCT/US2020/032686 WO2020232130A1 (en) 2019-05-14 2020-05-13 Dosing of kras inhibitor for treatment of cancers

Publications (2)

Publication Number Publication Date
NZ782000A NZ782000A (en) 2025-03-28
NZ782000B2 true NZ782000B2 (en) 2025-07-01

Family

ID=

Similar Documents

Publication Publication Date Title
Niu et al. Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC
Lissoni Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms
JP2022009090A5 (en)
CA2319872C (en) Pharmaceutical composition for the treatment of hepatocellular carcinoma
JP2017505321A5 (en)
NZ784949A (en) Ripretinib for treating gastrointestinal stromal tumors
KR20180048804A (en) Combination therapy with baritinib and anticancer drugs
CN112888458A (en) Combination therapy of antibodies to CLDN18 and chemotherapeutic agents
Tewes et al. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study
WO2021063332A1 (en) Use of ezh2 inhibitor combined with cdk4/6 inhibitor in preparation of drug for treating tumor
JP2023102787A5 (en)
MX2022006566A (en) Combination therapies for treatment of breast cancer.
US12023334B2 (en) Composition including rilpivirine and method for treating tumors or cancer
NZ782000B2 (en) Dosing of kras inhibitor for treatment of cancers
CA2554463C (en) Anti-cancer therapies
Wang et al. Preclinical investigation of orally bioavailable, potent KRAS Multi inhibitor JAB-23425
NZ782000A (en) Dosing of kras inhibitor for treatment of cancers
JPWO2020229626A5 (en)
JPWO2019196764A5 (en)
Wander et al. Abstract PO2-20-03: VERITAC-3: A randomized phase 3 study, with a lead-in, of first-line vepdegestrant+ palbociclib vs letrozole+ palbociclib in estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer
JPWO2022260132A5 (en)
Czito et al. A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma
Iurlo et al. Palmar-Plantar Erythrodysaesthesia Syndrome Due to 5-Fluorouracil Therapy–An Underestimated Toxic Event?
JPWO2021022256A5 (en)
Woessner et al. ARRY-162, a potent and selective MEK 1/2 inhibitor, shows enhanced efficacy in combination with other targeted kinase inhibitors and with chemotherapy